Dxcover is a clinical-stage cancer diagnostics company developing innovative technologies for the early detection of cancer. Its proprietary PANAROMIC™ platform combines multiomic spectral analysis with artificial intelligence to identify cancer from a simple blood sample, helping to improve diagnostic accuracy and enable earlier intervention.
Founded as a spin-out from the University of Strathclyde, Dxcover has established a strong position in the emerging liquid biopsy and cancer diagnostics market. The company’s low cost, rapid testing platform is designed to improve the detection of high-mortality and difficult-to-diagnose cancers, while supporting its expansion across the UK, Europe and the US.
This round of investment will further advance our mission to transform cancer diagnostics. It will accelerate our expansion into the United States and drive commercialisation in the UK & EU. This funding is a testament to our vision of improving outcomes and the quality of life by the earlier detection of cancer. It enables us to advance our differentiated technology and reach far more lives.
Professor Matthew J. Baker, Co-Founder, CEO and President of Dxcover
Meet the lead executive(s)
Subscribe for email updates
Door and Gate specialists secure MEIF II backing to support growth
Maven backs NunaBio through NPIF II Maven Equity Finance
Maven strengthens North East team with two new appointments
Bdaily secures six-figure investment to fuel national expansion
North East businesses benefit from share of £275m as NPIF II marks second anniversary
